Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expectation to outperform the benchmark index by over 20% in the next six months [1][17]. Core Insights - The company reported significant growth in Q2, with a year-on-year revenue increase of 17.80% and a quarter-on-quarter increase of 15.37%. The net profit for Q2 also saw a year-on-year rise of 20.77% and a quarter-on-quarter increase of 25.39% [7]. - The company is a leader in the long-chain dicarboxylic acid industry, with a strong focus on bio-based materials. It has established a production capacity of 115,000 tons for bio-based long-chain dicarboxylic acids and is expanding its product offerings [7]. - The company has increased its R&D investment, with a 23.1% year-on-year rise in R&D expenses, reflecting its commitment to developing a leading bio-based materials industry chain [7]. Financial Performance Summary - For 2025, the company is projected to achieve total revenue of 35.47 billion yuan, representing a year-on-year growth of 19.9%. The net profit is expected to reach 6.83 billion yuan, with a growth rate of 39.7% [2][8]. - The earnings per share (EPS) for 2025 is estimated at 0.95 yuan, with a price-to-earnings (P/E) ratio of 53.2 times [2][8]. - The company’s total assets are projected to grow to 25.35 billion yuan by 2025, with a debt-to-equity ratio of 6.7% [8]. Market Position and Strategy - The company is actively promoting its bio-based composite materials across various sectors, including textiles and engineering materials, and is developing new applications in renewable energy and automotive components [7]. - The establishment of new subsidiaries indicates the company's strategy to create an integrated bio-based materials industry chain, enhancing its market competitiveness [7].